Parvizi Surgical Innovation, LLC (PSI) has announced a minority investment in Aravis BioTech LLC (Aravis), a company specializing in X-ray visualized implanted sensors (X-VIS). These sensors are designed to quantitatively track fracture healing progress and evaluate infection risks within the affected area.
The investment in Aravis’ X-VIS technology aims to offer the medical community more precise assessments of fracture healing and early detection of infections, enabling timely interventions. Notably, Aravis sensors are visible on radiographic images, routinely obtained as part of standard patient care, and provide information about motion and local chemical concentrations. This innovation employs electronics-free mechanical gauges, known for their durability, simplicity in production, and user-friendliness. PSI is actively supporting Aravis in bringing this technology to market through additional research funding and collaborations with implant manufacturers.
Dr. Javad Parvizi, MD, the Founder of PSI and a globally recognized orthopedic surgeon specializing in orthopedic infections management, expressed his enthusiasm for Aravis’ technology: “Infections in a prosthetic joint, can significantly affect patients’ quality of life. Currently, joint fluid aspirations are the common method for infection detection, but having a sensor read through standard X-ray imaging would offer a faster, less painful, cost-effective, and lower-risk alternative.”
Parvizi Surgical Innovation, LLC (PSI) has announced a minority investment in Aravis BioTech LLC (Aravis), a company specializing in X-ray visualized implanted sensors (X-VIS). These sensors are designed to quantitatively track fracture healing progress and evaluate infection risks within the affected area.
The investment in Aravis’ X-VIS...
Parvizi Surgical Innovation, LLC (PSI) has announced a minority investment in Aravis BioTech LLC (Aravis), a company specializing in X-ray visualized implanted sensors (X-VIS). These sensors are designed to quantitatively track fracture healing progress and evaluate infection risks within the affected area.
The investment in Aravis’ X-VIS technology aims to offer the medical community more precise assessments of fracture healing and early detection of infections, enabling timely interventions. Notably, Aravis sensors are visible on radiographic images, routinely obtained as part of standard patient care, and provide information about motion and local chemical concentrations. This innovation employs electronics-free mechanical gauges, known for their durability, simplicity in production, and user-friendliness. PSI is actively supporting Aravis in bringing this technology to market through additional research funding and collaborations with implant manufacturers.
Dr. Javad Parvizi, MD, the Founder of PSI and a globally recognized orthopedic surgeon specializing in orthopedic infections management, expressed his enthusiasm for Aravis’ technology: “Infections in a prosthetic joint, can significantly affect patients’ quality of life. Currently, joint fluid aspirations are the common method for infection detection, but having a sensor read through standard X-ray imaging would offer a faster, less painful, cost-effective, and lower-risk alternative.”
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
